2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Serologic Tests, Blood Banking, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Gene Therapy, Non-Biological Therapies, Opioids, Workforce, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Diseases, Hemoglobinopathies, Sickle Cell Disease, Metabolic Disorders, Iron Overload, Research, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric
PAPER

4365 Hematopoietic cell transplantation for sickle cell disease: Qualitative findings of decision-making and experiences of patients and caregivers

Bhakti Chavda, PhD, Jane Brigden, PhD2, Kishan Desai, PhD3, Corey Jackson, PhD4, Tyler Russell, PhD5, Akshay Sharma Jr, MBBS6, Jerlym Porter, PhD, MPH7
1 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
2 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
3 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
4 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
5 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
6 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
7 St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Introduction

The decision to undergo hematopoietic cell transplantation (HCT) for patients with sickle cell disease (SCD) is complex. HCT for SCD is one of the most intense treatments for SCD, associated with both short- and long-term toxicities and a non-zero risk of mortality. Yet, this is one of the only opportunities to have a one-time cure and an SCD-free life. Further, understanding the experiences post-HCT are important to help patients have realistic expectations about the process and the outcomes. This study aims to determine factors that influence the decision to undergo HCT and explore perceptions of the HCT experience from the perspective of patients and caregivers.

Methods

Participants were patients with SCD ages 10-23 years who received either a matched sibling donor (MSD) or a haploidentical donor (HAPLO) HCT on an institutional clinical trial (NCT04362293) and their caregivers. Participants completed semi-structured interviews pre-and one-year post-HCT. Audio-recorded data were transcribed, coded, and organized into categories and themes.

Results

Fourteen patients (mean age=16.5±3.6 years; 57% male; 50% HAPLO) and 20 caregivers completed pre-HCT interviews, and 11 patients (mean age=15.7±4.0 years; 73% male; 55% HAPLO) and 17 caregivers completed post-HCT interviews.

Pre-HCT decision-making interviews: Doctors were the first source of exposure to HCT information for most participants, but 50% of participants also did their own research before speaking to the medical team. Most participants had a positive view of HCT prior to the process (53%) and felt that the benefits outweighed the risks. Participants expressed concerns about the HCT process and its impact on their future (38%), fertility (32%), and hair loss (29%). A third (32%) of participants reported that a transparent and detailed conversation with the medical team helped them feel more prepared for these concerns and yielded overall better understanding of the process. The most frequently reported reasons for undergoing HCT were improvement in quality of life (74%), worsening health status (65%), desire to achieve personal life goals (35%) and experience peer normalcy (29%), and current treatment ineffectiveness (20%). Quality of information received from the medical team was key in decision-making, and 70% of participants reported that the information presented was coherent. The decision to undergo HCT was often a joint one between patients and family members, with factors such as financial considerations and other parental responsibilities influencing the decision. Finally, participants reported that their spirituality and support from their family, community, and medical team contributed to their decision-making process.

Post-HCT interviews: 82% of participants reported having a positive HCT experience associated with improved quality of life and psychological outcomes and being disease-free, but 50% of participants reported at least some mismatch between expectations and actual HCT experience. Common reasons for mismatch were underestimation of hospital stay length, HCT side effect intensity, and stringent care routines post-HCT. Participants most frequently noted video games, TV, physical activity, spending time on the phone and social media, and spirituality as coping strategies, and identified friends, family, and the medical team as sources of support. Majority of participants (93%) endorsed HCT, but 23% of these participants indicated they would not undergo HCT again due to the intensity of side effects and the logistical, emotional, and physical demands of the procedure. Noted challenges were side effects (e.g., hair loss) and late effects (e.g., GVHD). Finally, participants expressed happiness and gratitude about HCT. They also reported fear of future uncertainty, regret of having undergone HCT due to intensity of side effects, treatment demands, and amount of time away from family and peers (7%) and regret for not having undergone HCT sooner (14%).

Conclusions

Findings underscore the importance of clear and transparent communication during the HCT decision-making process. Patients and families have varied HCT experiences and understanding these experiences will improve educating and preparing future families about HCT. Future studies will focus on integration of these findings with quantitative data and medical outcomes and long-term follow-up outcomes.

 

Bhakti Chavda, PhD: No relevant conflicts of interest to declare.